Our Team
Our team has extensive experience in healthcare analytics and industry dynamics, including senior executive responsibility for US Rx brand pricing in retail, hospital and specialty markets
Our Team
Our team has extensive experience in healthcare analytics and industry dynamics, including senior executive responsibility for US Rx brand pricing in retail, hospital and specialty markets
Dr. Richard Evans
Learn More
Scott Hinds
Learn More
Sophie Panzner
Learn More
Dr. Richard Evans
Richard is the general manager of SSR Health, which he founded in 2009. He is also the author of Health and Capital, an analysis of the US healthcare system and prospects for its reform.
From 1998 until 2006, Richard was a senior analyst at Sanford C. Bernstein, covering major pharmaceutical companies in the US. During his tenure, he was ranked first by both Institutional Investor and Bloomberg Markets for his sector recommendations. The latter publication also rated him as one of the top 20 stock-pickers globally across all large-cap industries.
From 1991 until 1998, Richard was a member of senior management at Roche. In his last role, he served as Vice President, Business Policy and Account Management, responsible for commercial interactions with large institutional buyers, including hospitals, hospital purchasing groups, managed-care organizations and governments. Before that, he served as head of Business Development and Strategic Planning and as product director for injectable anesthetics.
Richard earned a Doctor of Veterinary Medicine degree from North Carolina State University and a master’s in public and private management from Yale University. He also holds a patent (Number 8,353,866) for a cost-effective injection device intended to ease the preparation and delivery of injectable products requiring admixture before injections
Dr. Richard Evans
Richard is the general manager of SSR Health, which he founded in 2009. He is also the author of Health and Capital, an analysis of the US healthcare system and prospects for its reform.
From 1998 until 2006, Richard was a senior analyst at Sanford C. Bernstein, covering major pharmaceutical companies in the US. During his tenure, he was ranked first by both Institutional Investor and Bloomberg Markets for his sector recommendations. The latter publication also rated him as one of the top 20 stock-pickers globally across all large-cap industries.
From 1991 until 1998, Richard was a member of senior management at Roche. In his last role, he served as Vice President, Business Policy and Account Management, responsible for commercial interactions with large institutional buyers, including hospitals, hospital purchasing groups, managed-care organizations and governments. Before that, he served as head of Business Development and Strategic Planning and as product director for injectable anesthetics.
Richard earned a Doctor of Veterinary Medicine degree from North Carolina State University and a master’s in public and private management from Yale University. He also holds a patent (Number 8,353,866) for a cost-effective injection device intended to ease the preparation and delivery of injectable products requiring admixture before injection.
Scott Hinds
Scott is an experienced healthcare industry analyst and economist, and has primary responsibility for all pricing and R&D modeling at SSR Health. His expertise includes developing proprietary methodologies for analyzing large healthcare-related data sets, ranging in scope from employment-based health consumption dynamics to biopharma R&D productivity.
Before joining SSR Health in 2009, Scott was a strategic consultant at AVOS Life Sciences, an advisory firm. He specialized in large-scale quantitative projects for major pharmaceutical companies, targeting areas from development portfolio management to maximizing shareholder returns.
Scott began his career at Lehman Brothers, where he worked on the capital markets team responsible for IPOs, secondary offerings and PIPE (private investment in public equity) transactions for a broad range of healthcare, biotech and chemical companies.
He earned an MS in economics from the University of North Carolina at Chapel Hill, where he gained extensive experience in complex econometric techniques and taught both graduate and undergraduate microeconomics and mathematics. His work has been published in Nature Reviews Drug Discovery, Handbook of Public Finance and Reviews on Recent Clinical Trials.
Sophie Panzner
Sophie heads up sales at SSR Health, where she is also responsible for business development, marketing and client relationship management.
She began her career as an investment analyst before transitioning into institutional equity sales, with roles at leading global financial firms in New York, Paris and Los Angeles. In addition to the financial services industry, she has also served in a sales role in both the technology and healthcare sectors.
Sophie has a BA in Economics from Barnard College, Columbia University.
Dr. Denise Clayton
Denise is an experienced health economist leading new product development at SSR Health. Over her career, she has helped life sciences organizations, governments, payers, and providers navigate evolving payment and policy landscapes. Her experience includes real-world data analysis, policy impact analysis, cost-benefit analysis, mixed methods program evaluation, and supply and demand forecasting.
Prior to joining SSR Health, Denise was a Managing Director in the Center for Healthcare Economics and Policy at FTI Consulting. She led large-scale projects with key clients, using health insurance claims, publicly available data, and other sources to understand impact and inform data-driven decisions related to payment, policy, and technology innovations. In earlier roles, she led Health Economics and Evaluation research at RTI International, a non-profit research institute.
She began her career as a strategic consultant at AVOS Life Sciences, where she created tools for major pharmaceutical companies focused on strategy, innovation, and portfolio management.
Denise earned a PhD in Economics from the University of California at San Diego, where she applied innovative econometric techniques to large healthcare datasets. Her work has been published in the Journal of Health Economics, the Journal of Health Economics and Outcomes Research, the Journal of the American Pharmacists Association, and Nature Reviews Drug Discovery.